Iron supplements acutely increase hepcidin, but the duration and magnitude of the increase, its dose dependence and effects on subsequent iron absorption have not been characterized in humans. Better understanding of these phenomena might improve oral iron dosing schedules. We investigated whether the acute iron-induced increase in hepcidin influences iron absorption of successive daily iron doses and twice daily iron doses. We recruited 54 non-anemic young women with plasma ferritin ≤20 µg/l and conducted: 1) a dose-finding investigation with 40, 60, 80, 160 and 240 mg labeled Fe as [57Fe]-, [58Fe]- or [54Fe]-FeSO4 given at 8.00 fasting on one or on two consecutive days (study 1, n=25; study 2, n=16); and 2) a study giving three 60 mg Fe doses (twice a day dosing) within 24h (study 3, n=13). In studies 1 and 2, 24hr after doses of 60 mg or greater, serum hepcidin was increased (P<0.01) and fractional iron absorption was decreased by 35-45% (P<0.01). With increasing dose, fractional absorption decreased (P<0.001), while absolute absorption increased (P<0.001). A six-fold increase in iron dose (40 to 240 mg), resulted in only a 3-fold increase in iron absorbed (6.7 to 18.1 mg). In study 3, total iron absorbed from three doses (two mornings and afternoon) was not significantly greater than that from two morning doses. Providing lower dosages (40-80 mg Fe) and avoiding twice a day dosing maximizes fractional absorption. The duration of the hepcidin response supports alternate day supplementation, but longer-term effects of these schedules require further investigation. These clinical trials were registered at www.clinicaltrials.gov as NCT01785407 and NCT02050932.
Background: Vitamin A deficiency impairs iron metabolism; vitamin A supplementation of vitamin A–deficient populations may reduce anemia. The mechanism of these effects is unclear. In vitro and in animal models, vitamin A treatment increases the production of erythropoietin (EPO), a stimulant of erythropoiesis. Objective: We measured the effect of vitamin A supplementation on hemoglobin, iron status, and circulating EPO concentrations in children with poor iron and vitamin A status. Design: In a double-blind, randomized trial, Moroccan schoolchildren (n = 81) were given either vitamin A (200 000 IU) or placebo at baseline and at 5 mo. At baseline, 5 mo, and 10 mo, hemoglobin, indicators of iron and vitamin A status, and EPO were measured. Results: At baseline, 54% of children were anemic; 77% had low vitamin A status. In the vitamin A group at 10 mo, serum retinol improved significantly compared with the control group (P < 0.02). Vitamin A treatment increased mean hemoglobin by 7 g/L (P < 0.02) and reduced the prevalence of anemia from 54% to 38% (P < 0.01). Vitamin A treatment increased mean corpuscular volume (P < 0.001) and decreased serum transferrin receptor (P < 0.001), indicating improved iron-deficient erythropoiesis. Vitamin A decreased serum ferritin (P < 0.02), suggesting mobilization of hepatic iron stores. Calculated from the ratio of transferrin receptor to serum ferritin, overall body iron stores remained unchanged. In the vitamin A group at 10 mo, we observed an increase in EPO (P < 0.05) and a decrease in the slope of the regression line of log10(EPO) on hemoglobin (P < 0.01). Conclusion: In children deficient in vitamin A and iron, vitamin A supplementation mobilizes iron from existing stores to support increased erythropoiesis, an effect likely mediated by increases in circulating EPO.
Background: In many developing countries, children are at high risk of both goiter and iron deficiency anemia. Objective: In a series of studies in northern Morocco, we developed and tested a dual-fortified salt (DFS) containing iodine and microencapsulated iron. Design: To establish the DFS fortification concentration, we measured salt intake by 3-d weighed food records and estimated iron bioavailability from the local diet by using published algorithms. We then formulated a DFS containing 25 μg iodine/g salt (as potassium iodide) and 1 mg iron/g salt (as ferrous sulfate hydrate encapsulated with partially hydrogenated vegetable oil). After storage and acceptability trials, we compared the efficacy of the DFS to that of iodized salt in a 9-mo, randomized, double-blind trial in iodine-deficient, 6–15-y-old children (n = 377). Results: Mean salt intake in school-age children was 7–12 g/d, and estimated iron bioavailability from the local diet was 0.4–4.3%. After storage for 20 wk, the DFS and iodized salt were not significantly different in iodine content, and color stability was acceptable when the compounds were added to local meals. During the efficacy trial, urinary iodine concentrations and thyroid volumes improved significantly (P < 0.001 and < 0.05, respectively) from baseline in both groups. At 40 wk, mean hemoglobin concentrations in the DFS group had increased by 14 g/L (P < 0.01), and serum ferritin, transferrin receptor, and zinc protoporphyrin concentrations were significantly better (P < 0.05) in the DFS group than in the iodized salt group. The prevalence of iron deficiency anemia in the DFS group decreased from 35% at baseline to 8% at 40 wk (P < 0.001). Conclusion: A DFS containing iodine and encapsulated iron can be an effective fortification strategy.